BusinessMelinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United StatesBy Nasdaq OMXOct 30, 2017, 12:01 PM UTC
BusinessMelinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients with MRSA Infections and Challenging ComorbiditiesBy Nasdaq OMXOct 24, 2017, 12:01 PM UTC
BusinessMelinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeekBy Nasdaq OMXOct 4, 2017, 5:14 PM UTC
BusinessMelinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other InfectionsBy Nasdaq OMXSep 25, 2017, 12:01 PM UTC
BusinessMelinta Therapeutics to Participate in Two Upcoming Investor ConferencesBy Nasdaq OMXSep 22, 2017, 12:00 PM UTC
BusinessMelinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA PathogensBy Nasdaq OMXSep 18, 2017, 12:01 PM UTC
BusinessMelinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 CountriesBy Nasdaq OMXMar 2, 2017, 1:01 PM UTC
BusinessMelinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 CountriesBy Nasdaq OMXMar 2, 2017, 1:01 PM UTC
